aripiprazole has been researched along with Attention Deficit and Disruptive Behavioral Disorders in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (31.58) | 29.6817 |
| 2010's | 12 (63.16) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Bozduman, S; Guler Aksu, G | 1 |
| Baeza, I; de Castro, C; Espinosa, L; Fortea, A; Ilzarbe, D; Oriolo, G; Solerdelcoll, M; Sugranyes, G | 1 |
| Pringsheim, T; Shafiq, S | 1 |
| Fu, AT; Pan, PY; Yeh, CB | 1 |
| Anagnostou, E; Baribeau, DA | 1 |
| Antoniazzi, S; Auricchio, F; Bernardini, R; Bertella, S; Bravaccio, C; Capuano, A; Carnovale, C; Cattaneo, D; Clementi, E; Ferrajolo, C; Gentili, M; Guastella, G; Mani, E; Molteni, M; Pascotto, A; Pisano, S; Pozzi, M; Radice, S; Rafaniello, C; Riccio, MP; Rizzo, R; Rossi, F; Scuderi, MG; Sperandeo, S; Sportiello, L; Villa, L | 1 |
| Chang, KD | 1 |
| Findling, RL | 1 |
| McKinney, C; Renk, K | 1 |
| Carson, WH; Forbes, RA; Mankoski, R; Mathew, SJ; Zhao, J | 1 |
| Diaz-Atienza, F; Gurpegui, M; Gutiérrez-Rojas, L; Jurado, D; Martínez-Ortega, JM | 1 |
| Akyol Ardic, U; Ardıc, UA; Ercan, E; Ercan, ES; Uysal, T | 1 |
| Magno Zito, J; Safer, AM; Safer, DJ | 1 |
| Stern, AP; Trieu, ML | 1 |
| Honaker, J; Lohr, WD | 1 |
| Buck, ML; Davenport, JD; McCarthy, MW | 1 |
| Janvier, YM; Rugino, TA | 1 |
| Demb, H; Valicenti-McDermott, MR | 1 |
| Cooper, T; Usubiaga, H; Winsberg, B | 1 |
7 review(s) available for aripiprazole and Attention Deficit and Disruptive Behavioral Disorders
| Article | Year |
|---|---|
Using antipsychotics for behavioral problems in children.
Topics: Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Autism Spectrum Disorder; Child; Humans; Irritable Mood; Randomized Controlled Trials as Topic; Risperidone | 2018 |
An update on medication management of behavioral disorders in autism.
Topics: Adolescent; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Autistic Disorder; Central Nervous System Stimulants; Child; Clinical Trials as Topic; Humans; Piperazines; Propylamines; Quinolones; Risperidone | 2014 |
The use of atypical antipsychotics in pediatric bipolar disorder.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Bipolar Disorder; Child; Comorbidity; Dibenzothiazepines; Disorders of Excessive Somnolence; Humans; Obesity; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles; Weight Gain | 2008 |
Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Benzodiazepines; Child; Dibenzothiazepines; Disorders of Excessive Somnolence; Headache; Humans; Methylphenidate; Obesity; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone | 2008 |
Atypical antipsychotic medications in the management of disruptive behaviors in children: safety guidelines and recommendations.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Benzodiazepines; Child; Humans; Olanzapine; Piperazines; Practice Guidelines as Topic; Quinolones; Risperidone; Treatment Outcome | 2011 |
Age-grouped differences in bipolar mania.
Topics: Adolescent; Adult; Age Factors; Aggression; Anger; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Benzodiazepines; Bipolar Disorder; Child; Clinical Trials as Topic; Comorbidity; Defense Mechanisms; Female; Humans; Irritable Mood; Male; Middle Aged; Motor Activity; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychometrics; Quinolones; Sexual Behavior; Thinking; Young Adult | 2012 |
Atypical antipsychotics for the treatment of disruptive behavior.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Benzodiazepines; Child; Clozapine; Dibenzothiazepines; Drug Interactions; Drug Monitoring; Humans; Olanzapine; Pediatrics; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone | 2013 |
4 trial(s) available for aripiprazole and Attention Deficit and Disruptive Behavioral Disorders
| Article | Year |
|---|---|
Aripiprazole/Methylphenidate Combination in Children and Adolescents with Disruptive Mood Dysregulation Disorder and Attention-Deficit/Hyperactivity Disorder: An Open-Label Study.
Topics: Adolescent; Antidepressive Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Comorbidity; Drug Therapy, Combination; Female; Humans; Male; Methylphenidate; Neuropsychological Tests | 2018 |
Young mania rating scale line item analysis in pediatric subjects with bipolar I disorder treated with aripiprazole in a short-term, double-blind, randomized study.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Child; Comorbidity; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Inpatients; Male; Outpatients; Piperazines; Placebos; Psychiatric Status Rating Scales; Quinolones; Time Factors; Treatment Outcome | 2011 |
Aripiprazole in children and adolescents with conduct disorder: a single-center, open-label study.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Child; Diagnostic and Statistical Manual of Mental Disorders; Dopamine Agonists; Drug Monitoring; Drug Resistance; Female; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Receptors, Dopamine D2; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Severity of Illness Index; Turkey | 2012 |
Ghrelin and leptin response to oral glucose challenge among antipsychotic drug-treated children.
Topics: Administration, Oral; Adolescent; Age Factors; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Blood Glucose; Body Mass Index; Child; Chlorpromazine; Fasting; Female; Ghrelin; Glucose; Glucose Tolerance Test; Humans; Insulin; Leptin; Male; Piperazines; Quinolones; Risperidone; Sex Factors; Time Factors; Weight Gain | 2007 |
8 other study(ies) available for aripiprazole and Attention Deficit and Disruptive Behavioral Disorders
| Article | Year |
|---|---|
Aripiprazole-induced bruxism in a child: A case report.
Topics: Affective Symptoms; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Child; Humans; Male; Serotonin 5-HT1 Receptor Agonists; Sleep Bruxism | 2020 |
Long-Acting Injectable Atypical Antipsychotic Use in Adolescents: An Observational Study.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Child; Delayed-Action Preparations; Female; Hospitalization; Humans; Inpatients; Male; Off-Label Use; Paliperidone Palmitate; Psychiatric Status Rating Scales; Psychotic Disorders; Retrospective Studies; Risperidone; Treatment Outcome | 2018 |
Persistence in Therapy With Risperidone and Aripiprazole in Pediatric Outpatients: A 2-Year Naturalistic Comparison.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Child; Female; Follow-Up Studies; Humans; Male; Medication Adherence; Mental Disorders; Outcome Assessment, Health Care; Outpatients; Risperidone; Sex Factors; Tic Disorders | 2016 |
Confounding by indication of a specific antipsychotic and the increase of body mass index among children and adolescents.
Topics: Adolescent; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Benzodiazepines; Bipolar Disorder; Body Mass Index; Body Weight; Child; Dibenzothiazepines; Female; Follow-Up Studies; Humans; Male; Mental Disorders; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Spain; Time Factors | 2011 |
A case of antipsychotic-induced hyperglycemia in a child with insulin dependent diabetes mellitus.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Blood Glucose; Diabetes Mellitus, Type 1; Hospitalization; Humans; Hyperglycemia; Language Disorders; Learning Disabilities; Male; Piperazines; Quinolones; Risperidone | 2012 |
Excessive somnolence from aripiprazole in a child.
Topics: Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Child; Disorders of Excessive Somnolence; Female; Humans; Piperazines; Quinolones | 2004 |
Aripiprazole in children and adolescents: clinical experience.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Bipolar Disorder; Child; Child Behavior Disorders; Child, Preschool; Dose-Response Relationship, Drug; Female; Humans; Male; Piperazines; Prospective Studies; Quinolones; Retrospective Studies; Treatment Outcome; Treatment Refusal | 2005 |
Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities.
Topics: Adolescent; Aggression; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Body Mass Index; Child; Child Behavior Disorders; Child, Preschool; Dose-Response Relationship, Drug; Drug Approval; Female; Follow-Up Studies; Humans; Impulsive Behavior; Intellectual Disability; Male; Mood Disorders; Piperazines; Quinolones; Reactive Attachment Disorder; Self-Injurious Behavior; Sleep Wake Disorders | 2006 |